SCHEDULE 13G/A: BB Biotech AG and Subsidiary Disclose 15.1% Stake in Black Diamond Therapeutics
Beneficial Ownership Report
BB Biotech AG and its wholly-owned subsidiary, Biotech Growth N.V., have disclosed a combined beneficial ownership of 15.1% in Black Diamond Therapeutics, Inc., holding 8,517,839 shares of common stock as of December 31, 2024.
Summary
- BB Biotech AG, a Swiss entity, and its wholly-owned subsidiary, Biotech Growth N.V., based in Curacao, have filed an Amendment No. 5 to their Schedule 13G.
- The filing reports their beneficial ownership in Black Diamond Therapeutics, Inc. (CUSIP: 09203E105).
- As of December 31, 2024, the reporting persons collectively beneficially own 8,517,839 shares of Black Diamond Therapeutics' Common Stock.
- This aggregate amount represents 15.1% of the issuer's class of securities.
- Both BB Biotech AG and Biotech Growth N.V. hold shared voting power and shared dispositive power over all 8,517,839 shares.
- The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, consistent with a passive investment under Rule 13d-1(b).
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational or financial news.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.
Industry Context
This filing indicates a significant, passive investment by a biotech-focused investment firm in Black Diamond Therapeutics, a company operating in the biotechnology sector. Such disclosures are common for institutional investors accumulating substantial stakes in public companies, particularly within specialized sectors like biotech.
Stakeholder Impact
- Shareholders: The disclosure of a significant 15.1% stake by a major investment firm like BB Biotech AG could be viewed positively by other shareholders, signaling institutional confidence in Black Diamond Therapeutics. It also provides transparency regarding the ownership structure.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period for beneficial ownership). |
| 02/12/2025 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
Black Diamond Therapeutics, BB Biotech AG, Biotech Growth N.V., SEC filing, Schedule 13G, beneficial ownership, common stock, biotechnology, investment, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.